Neuroscience
Neurofilament-L Blocking Peptide
|
イイネ!(0)
|
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1005S | 100 μg | 16,000 | |
|
Neurofilament-L抗体製品一覧
| 使用目的 | |
| Neurofilament-L (C28E10) Rabbit mAb (#2837) の反応をブロックし、抗体の反応特異性を確認するために使用 |
IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded mouse brain using Neurofilament-L (C28E10) Rabbit mAb #2837 in the presence of control peptide (left) or Neurofilament-L Blocking Peptide (right).
The cytoskeleton consists of three types of cytosolic fibers: actin microfilaments, intermediate filaments, and microtubules. Neurofilaments are the major intermediate filaments found in neurons and consist of light (NFL), medium (NFM), and heavy (NFH) subunits (1). Similar in structure to other intermediate filament proteins, neurofilaments have a globular amino-terminal head, a central α-helical rod domain, and a carboxy-terminal tail. A heterotetrameric unit (NFL-NFM and NFL-NFH) forms a protofilament, with eight protofilaments comprising the typical 10 nm intermediate filament (2). While neurofilaments are critical for radial axon growth and determine axon caliber, microtubules are involved in axon elongation. PKA phosphorylates the head domain of NFL and NFM to inhibit neurofilament assembly (3,4). Neurofilament accumulations are found in many human neurological disorders including Parkinson's disease (in Lewy bodies along with α-synuclein), Alzheimer's disease, Charcot-Marie-Tooth disease, and Amyotrophic Lateral Sclerosis (ALS) (1).
-
Al-Chalabi, A. and Miller, C.C. (2003) Bioessays 25, 346-355.
-
Cohlberg, J.A. et al. (1995) J. Biol. Chem. 270, 9334-9339.
-
Hisanaga, S. et al. (1994) Mol. Biol. Cell 5, 161-172.
-
Sihag, R.K. et al. (1999) J. Neurochem. 72, 491-499.